GlaxoSmithKline plc (GSK) Stock Rating Reaffirmed by BNP Paribas
GlaxoSmithKline plc (LON:GSK)‘s stock had its “underperform” rating restated by stock analysts at BNP Paribas in a note issued to investors on Friday. They presently have a GBX 1,520 ($19.84) price objective on the stock. BNP Paribas’ price objective indicates a potential downside of 8.71% from the company’s previous close.
Several other analysts have also issued reports on the company. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a report on Monday, June 20th. HSBC reiterated a “buy” rating and set a GBX 1,970 ($25.71) target price on shares of GlaxoSmithKline plc in a report on Monday, September 12th. Deutsche Bank AG reiterated a “hold” rating on shares of GlaxoSmithKline plc in a report on Monday, June 27th. Berenberg Bank set a GBX 1,885 ($24.61) target price on GlaxoSmithKline plc and gave the stock a “neutral” rating in a report on Tuesday, August 9th. Finally, Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline plc in a report on Tuesday, June 21st. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have given a buy rating to the company. GlaxoSmithKline plc has an average rating of “Hold” and a consensus target price of GBX 1,676.44 ($21.88).
Shares of GlaxoSmithKline plc (LON:GSK) opened at 1693.50 on Friday. The stock’s 50 day moving average price is GBX 1,643.83 and its 200 day moving average price is GBX 1,546.01. The firm’s market cap is GBX 82.32 billion. GlaxoSmithKline plc has a one year low of GBX 1,277.25 and a one year high of GBX 1,716.50.
The business also recently announced a dividend, which will be paid on Thursday, October 13th. Investors of record on Thursday, August 11th will be given a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.12%. The ex-dividend date of this dividend is Thursday, August 11th.
In related news, insider Slaoui,Moncef bought 28 shares of the stock in a transaction that occurred on Friday, August 12th. The stock was acquired at an average cost of GBX 2,208 ($28.82) per share, with a total value of £618.24 ($807.00). Also, insider Witty,Sir Andrew P sold 10,000 shares of the firm’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($22.10), for a total value of £169,300 ($220,989.43).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.